Basic information about memantine and its treatment of Alzheimer's disease and other clinical applications
Abstract Memantine is a noncompetitive moderate‐affinity strong voltage‐dependent N‐methyl‐D‐aspartate receptor antagonist. It has been used to treat Alzheimer's disease (AD) since 1989. In 2018, it became the second most commonly used drug for the treatment of dementia in the world. AD is nonr...
Main Authors: | Bin‐Can Tang, Ya‐Ting Wang, Jie Ren |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley-VCH
2023-09-01
|
Series: | Ibrain |
Subjects: | |
Online Access: | https://doi.org/10.1002/ibra.12098 |
Similar Items
-
Memantine-Assisted Treatment of N-Methyl-D-Aspartate Receptor Antibody Encephalitis: A Mini Review
by: Liu FX, et al.
Published: (2024-12-01) -
The Effect of Add-on Memantine in New Onset Combat-Related Posttraumatic Stress Disorder Core Symptoms: A Pilot Study
by: Fatemeh Rajabi, et al.
Published: (2023-06-01) -
Efficacy of memantine premedication in alleviating postoperative pain- A systematic review and meta-analysis
by: Abhijit Nair, et al.
Published: (2024-01-01) -
Intrastriatal Memantine Infusion Dampens Levodopa-Induced Dyskinesia and Motor Deficits in a Mouse Model of Hemiparkinsonism
by: Masatoshi Ogawa, et al.
Published: (2019-12-01) -
Eficácia da memantina na doença de Alzheimer em seus estágios moderado a grave Efficacy of memantine in moderate to severe Alzheimer disease
by: Rosana Soares Araújo, et al.
Published: (2006-01-01)